# Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

> **NCT00035464** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 431 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Azimilide Dihydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00035464
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 431 (ACTUAL)
- **Last updated:** 2011-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035464, "Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00035464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*